Nurix Therapeutics announces encouraging findings from the ongoing clinical study of its BTK degrader NX-5948 in patients with relapsed/refractory Waldenström’s macroglobulinemia.

Zymeworks has reported that the initial patient has been dosed in a Phase 1 clinical trial assessing ZW171 for advanced cancers that express mesothelin.

REGENXBIO shares favorable results from the Phase II trial of subretinal ABBV-RGX-314 for bilateral wet AMD patients at AAO 2024.

Adcentrx Therapeutics has received FDA approval for its Investigational New Drug application for ADRX-0405, a promising first-in-class ADC aimed at STEAP1.

BOTOX® Cosmetic (onabotulinumtoxinA) is now FDA-approved for treating moderate to severe vertical neck bands (platysma bands).

AstraZeneca submitted a market application for the injectable drug Tremelimumab.

LaNova Medicines has begun a Phase 1 clinical trial for its bispecific antibody LM-299 targeting PD-1 and VEGF, and has finalized a Series C1 funding round of $42 million.

Nurix Therapeutics unveiled promising data from its Phase 1a/1b clinical trial of NX-5948 at the 12th International Workshop on Waldenstrom's Macroglobulinemia.

Genentech's Vabysmo enhanced vision in underserved groups with Diabetic Macular Edema (DME) in a groundbreaking study.

Astellas’ VYLOY™ (zolbetuximab-clzb) has received U.S. FDA approval for treating advanced gastric and GEJ cancers.

Tenaya Therapeutics provides updates on its TN-201 gene therapy project targeting MYBPC3-related HCM.

ARTHEx Biotech has initiated dosing for the first patient in the Phase I-IIa trial of ArthemiR™ for Myotonic Dystrophy Type 1 (DM1).